Dihydroergotoxine (mesylate)

Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl- channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity[1][2][3][4][5][6][7][8][9].Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl- channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity[1][2][3][4][5][6][7][8][9].

Product Specifications

CAS Number

[8067-24-1]

Product Name Alternative

Ergoloid mesylates

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor; Chloride Channel; Dopamine Receptor; GABA Receptor; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Dihydroergotoxine_mesylate.html

Purity

99.61

Solubility

DMSO : 175 mg/mL (ultrasonic)

Smiles

[H][C@]1([C@]2([H])C[C@@H](C(N[C@@]3(C(C)C)C(N([C@@H]([R])C(N4[C@@]5([H])CCC4)=O)[C@@]5(O)O3)=O)=O)CN1C)CC6=CNC7=C6C2=CC=C7.CCC8=CC=CC=C8.CC(C)C.CC(CC)C.CC(C)CC.OS(=O)(C)=O

Precautions

H302

References & Citations

[1]Tvrdeic A, et al. Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202 (1) :109-11. |[2]Tvrdeic A, et al. Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82.|[3]Abdul M, et al. Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol. 2008;47 (8) :1546-50.|[4]Cheng YQ, Ge NN, Zhu HH, Sha ZT, Jiang T, Zhang YD, Tian YY. Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease. Parkinsonism Relat Disord. 2019 Jan;58:70-73. |[5] Izumiyama K, Kogure K. Effect of dihydroergotoxine mesylate (Hydergine) on delayed neuronal death in the gerbil hippocampus. Acta Neurol Scand. 1988 Sep;78 (3) :214-20. |[6]Gygax P, et al. Effect of papaverine and dihydroergotoxine mesylate on cerebral microflow, EEG, and pO2 in oligemic hypotension. Gerontology. 1978;24 Suppl 1:14-22.|[7]Enz A, et al. The influence of dihydroergotoxine mesylate on the low-Km phosphodiesterase of cat and rat brain in vitro. Gerontology. 1978;24 Suppl 1:115-25. |[8]Carruthers-Jones DI, et al. Changes in the rat electrocorticogram following administration of two dihydrogenated ergot derivatives. Gerontology. 1978;24 Suppl 1:23-33.|[9]Memo M, et al. Dihydroergotoxine decreases blood pressure in spontaneously hypertensive rats by interacting with peripheral dopamine receptors. Life Sci. 1985 Apr 22;36 (16) :1515-22.